Sponsor: Martin, Brock Full bill history + details: Automated legislative tracking by LegisGo #TNLeg #TennesseePolitics To view or add a comment, sign in Dr
E., Cui, X., Benson, C., Milicevic, Z
Manufacturers Must Adapt to Growing GLP-1 and GIP/GLP-1 RA Markets Summary As the GLP-1 product market continues to expand, manufacturers must find ways to differentiate their inline and pipeline assets with new evidence and strong value story
Inositol trials demonstrate improved body composition, with 35% more fat loss and maintained or increased muscle mass (PMID 30915778
The escalation schedule also reduces discontinuation rates caused by intolerance, meaning more people stay on treatment long enough to see results
V., Geller, M